![[Search]](/static/images/search.gif){kind=small}
![[A-Z Index]](/static/images/az.gif){kind=small}
![[Contact]](/static/images/contact.gif){kind=small}
![[University of Cambridge]](/static/images/identifier2.gif){kind=small}
![[Talks.cam]](/static/images/talkslogosmall.gif)
Prof. Mark Cragg - Faculty of Medicine, University of Southampton
Thursday 27 June 2013, 13:30-14:30
Fc Receptors: Critical regulators of antibody biology and therapy
- đ¤ Speaker: Prof. Mark Cragg - Faculty of Medicine, University of Southampton
- đ Date & Time: Thursday 27 June 2013, 13:30 - 14:30
- đ Venue: MPLT, MRC-LMB, Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0QH
Abstract
Monoclonal antibodies (mAb) represent a growing class of ‘block-buster’ cancer drugs, led by established reagents such as rituximab, trastuzumab, and bevacizumab. Despite such success, we are only now starting to understand how these drugs work and therefore how they can be augmented for better efficacy. We have understood for some time that Fc gamma receptors (FcR) on effector cells are critical for the in-vivo efficacy of direct-targeting mAb. However, recent data from our lab and others indicates that the situation is more complex than first appreciated. In this talk, data will be presented revealing novel ways in which the biology of FcR can regulate mAb activity with clear implications for subsequent design of future reagents. In particular the inhibitory FcR (CD32B) will be explored as a target for manipulating various forms of immunotherapy.
Series This talk is part of the Cambridge Immunology series.
Included in Lists
- All Talks (aka the CURE list)
- Cambridge Immunology
- Cambridge Immunology Network Seminar Series
- Cambridge Infectious Disease
- Cambridge Infectious Diseases
- Liam
- LMB
- MPLT, MRC-LMB, Francis Crick Avenue, Cambridge Biomedical Campus, CB2 0QH
- Pathology Seminars
Note: Ex-directory lists are not shown.